Click here to search courses using NAPNAP's previous Course Catalog layout.

Title
Category
Credits
Event date
Cost
Managing the Acutely Aggressive Child - 2023Conf
  • Mental Health
  • Pharmacology CE
  • Psychopharmacology CE
  • 1.25 Contact hours
$25.00
1.25 NAPNAP Contact Hour of which 1.25 contain pharmacology content and 0.5 is related to psychopharmacology. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $12.50 for NAPNAP Members. For non-members, this continuing education activity rate is $25. This course is an archived presentation from NAPNAP's 2023 National Conference and is offered free with a coupon for conference attendees until 12/31/23. Caring for the acutely aggressive child is challenging for novice to seasoned APRNs working with children and adolescents in an acute care setting. This presentation will provide evidence-based strategies to help improve the quality of care provided to children with acute aggression while increasing provider confidence when caring for this population. This discussion will include case-based scenarios and discussion of pharmacologic and non-pharmacologic care approaches.
2023 Pediatric Rx: Module 5- Psychotropic Medications
  • Mental Health
  • Pharmacology CE
  • Psychopharmacology CE
  • 1.00 Contact hours
$20.00
1.0 NAPNAP contact hour, of which 1.0 is Pharmacology and 1.0 Psychopharmacology. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity rate is $10 for NAPNAP Members. For non- members, this continuing education activity rate is $20. An extensive review will provide the participant with up-to-date information about commonly used antidepressants and atypical antipsychotics.
JPHC CE: Approaches to Treating Children With ADHD and Common Comorbidities
  • FREE for Members
  • Pharmacology CE
  • Psychopharmacology CE
  • Controlled Substances CE
  • 1.00 Contact hours
$10.00
1.0 NAPNAP contact hour of which 1.0 contain pharmacology content (Rx), (1.0 is related to psychopharmacology), (0.25 is related to controlled substance). This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Attention Deficit Hyperactivity Disorder (ADHD) is the most common mental health disorder among children and adolescents, with a prevalence rate of 9.8% in children 3 to 17 years of age (Bitsko et al., 2022). The American Academy of Pediatrics (AAP) has published guidelines for treatment of ADHD in children and adolescents ages 4 to 17 years that address diagnosis, treatment and monitoring of ADHD (Wolraich et al., 2019). The AAP guidelines do not address treatment of children with co-morbidities but identify the treatment of ADHD in children with comorbidities as an area for future research. To address this gap, a review of ADHD treatment in children with comorbidities including anxiety, depression, substance use disorder (SUD), epilepsy, tic disorders (TD), oppositional defiant disorder (ODD), learning disabilities (LD), autism spectrum disorder (ASD) and sleep disorders was conducted. J Pediatr Health Care. (2025) 39, 318-325.